MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme
Oxford, England, 3rd October 2024 – MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted therapeutics in obesity-related disorders and myopathies announces the appointment of experienced pharma business development executive Dr. David Holbrook as an independent Non-Executive Director (NED), and world-renowned diabetologist and clinical triallist, Professor Rury Holman, to its Scientific Advisory Board (SAB), as MitoRx initiates its obesity programme.
